Roth MKM downgraded Cyclacel Pharmaceuticals (CYCC) to Neutral from Buy.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYCC:
- Cyclacel reports clinical data from Phase 2 study of oral fadraciclib
- Biotech Alert: Searches spiking for these stocks today
- Cyclacel Pharmaceuticals files to sell common stock, warrants, no amount given
- Cyclacel completes enrollment in Cohort 8 of Phase 2 study of fadraciclib
- Cyclacel Pharmaceuticals confirms filing of appeal to Nasdaq delisting letter